Generating drug resistance models in human and murine cancer cell lines and assessing cross-resistance to chemotherapeutics and KRAS inhibitors

Drug resistance and cross-resistance limit the durability of cancer therapies, yet reproducible in vitro techniques for generating resistant models remain limited. Here, we present a protocol for generating human and murine cancer cell lines with drug resistance to chemotherapeutics and KRAS inhibitors. We describe steps for generating, expanding, and maintaining resistant cells. We then detail procedures for validating drug resistance and cross-resistance, followed by a quantitative killing assay. This approach facilitates the evaluation of resistance and cross-resistance liabilities of compounds. For complete details on the use and execution of this protocol, please refer to Gujar et al. 1

Authors

Institutions

Publication Details

Journal
STAR Protocols
Published
2026-06-26
DOI
https://doi.org/10.1016/j.xpro.2026.104649
Primary Topic
Protein Kinase Regulation and GTPase Signaling
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Generating drug resistance models in human and murine cancer cell lines and assessing cross-resistance to chemotherapeutics and KRAS inhibitors

Ravindra Gujar, Maria Fumagalli, Lev Becker, Chang Cui et al.
STAR Protocols
Protein Kinase Regulation and GTPase Signaling
article

Generating drug resistance models in human and murine cancer cell lines and assessing cross-resistance to chemotherapeutics and KRAS inhibitors

Ravindra Gujar, Maria Fumagalli, Lev Becker, Chang Cui, Nicole Martinez
article en

Abstract

Drug resistance and cross-resistance limit the durability of cancer therapies, yet reproducible in vitro techniques for generating resistant models remain limited. Here, we present a protocol for generating human and murine cancer cell lines with drug resistance to chemotherapeutics and KRAS inhibitors. We describe steps for generating, expanding, and maintaining resistant cells. We then detail procedures for validating drug resistance and cross-resistance, followed by a quantitative killing assay. This approach facilitates the evaluation of resistance and cross-resistance liabilities of compounds. For complete details on the use and execution of this protocol, please refer to Gujar et al. 1

STAR ProtocolsVol. 7(3)
MEI Pharma (United States) (US), OncoGenex Pharmaceuticals (United States) (US)
Good health and well-being
Openalex Percentile: Top 10%
Protein Kinase Regulation and GTPase Signaling
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Generating drug resistance models in human and murine cancer cell lines and assessing cross-resistance to chemotherapeutics and KRAS inhibitors — Ravindra Gujar, Maria Fumagalli, et al. · STAR Protocols (2026) | TGRS Research Map | TGRS